Human T cell immunodeficiency
Tóm tắt
Severe combined immunodeficiency (SCID) is a heterogeneous group of diseases that are invariably fatal in infancy unless treated by hematopoietic stem cell replacement. For many years we have worked to better manage patients affected by SCID through rapid and accurate diagnosis followed by treatment aimed at achieving long-lasting immune reconstitution. By extensive immunological, biochemical, and genetic studies of patient samples, and with the realization of differences between human and murine T cell development, we have successfully been able to identify some of the molecular defects causing SCID. Among these discoveries, we described the first mutated signal transduction protein in T cells (ZAP-70); the first genetic defect leading to SCID and autoimmune phenomena (IL2Rα); and, recently, the critical importance of CD3δ in the development of T cells. Our efforts have significantly advanced the understanding of the role of some of the signal-transducing proteins in T cell maturation and function. This review summarizes several of these discoveries and some of their impact on our understanding of T cells development, function, and homeostasis in humans.
Tài liệu tham khảo
Huang H, Manton KG: Newborn screening for severe combined immunodeficiency (SCID): a review. Front Biosci 2005;10:1024–1039.
Stein R, Hummel D, Bohn D, Levison H, Roifman CM: Lymphocytic pneumonitis following bone marrow transplantation in severe combined immunodeficiency. Am Rev Respir Dis 1991;143:1406–1408.
Dalal I, Reid B, Doyle J, et al.: Matched unrelated bone marrow transplantation for combined immunodeficiency. Bone Marrow Transplant 2000;25:613–621.
Candotti F, Roifman C, Puck JM: Immunodeficiencies: injecting some safety into SCID gene therapy? Gene Ther 2006;13:741–743.
Zhang J, Quintal L, Atkinson A, Williams B, Grunebaum E, Roifman CM: Novel RAG1 mutation in a case of severe combined immunodeficiency. Pediatrics 2005;116:e445–449.
Roifman CM: Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans. Immunol Rev 2005;203:143–155.
Doherty PJ, Pan S, Mulloy JC, et al.: Adenosine deaminase and thymocyte maturation. Scand J Immunol 1991;33:405–410.
Grunebaum E, Zhang J, Roifman CM: Novel mutations and hot-spots in patients with purine nucleoside phosphorylase deficiency. Nucleosides Nucleotides Nucleic Acids 2004;23:1411–1415.
Melamed I, Cohen A, Roifman CM: Expansion of CD3+CD4-CD8- T cell population expressing high levels of IL-5 in Omenn's syndrome. Clin Exp Immunol 1994;95:14–21.
Roifman CM, Mills GB, Cheung RK, Gelfand EW: Mitogenic response of human thymocytes: identification of functional Ca2+-dependent and independent signals. Clin Exp Immunol 1986;66(1):139–149.
Roifman CM: A mutation in zap-70 protein tyrosine kinase results in a selective immunodeficiency. J Clin Immunol 1995;15:52S-62S.
Arpaia E, Shahar M, Dadi H, Cohen A, Roifman CM: Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 76:947–958.
Elder ME, Skoda-Smith S, Kadlecek TA, Wang F, Wu J, Weiss A: Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 2001;166:656–661.
Wiest DL, Ashe JM, Abe R, Bolen JB, Singer A: TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56lck. Immunity 1996;4:495–504.
Gelfand EW, Weinberg K, Mazer BD, Kadlecek TA, Weiss A: Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes. J Exp Med 1995;182(4):1057–1065.
Toyabe S, Watanabe A, Harada W, Karasawa T, Uchiyama M: Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology 2001; 103:164–171.
Sakaguchi N, Takahashi T, Hata H, et al: Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426:454–460.
Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW: Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3(4):521–530.
Roifman CM: A novel immunodeficiency: interleukin-2 receptor-α deficiency causes immunodeficiency and autoimmunity. Can J Allergy Clin Immunol 1997;2: 30–33.
Sharfe N, Dadi HK, Shahar M, Roifman CM: Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci USA 1997;94:3168–3171.
Roifman CM: Human IL-2 receptor alpha chain deficiency. Pediatr Res 2000;48:6–11.
Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D: The cellular mechanism of Aire control of T cell tolerance. Immunity 2005;23:227–239.
Ochs HD, Ziegler SF, Torgerson TR: FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005; 203:156–164.
Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, et al: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147–157.
Grunebaum E, Zhang J, Dadi H, Roifman CM: Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br J Haematol 2000;108:834–837.
Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ: Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127–142.
Sharfe N, Shahar M, Roifman CM: An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Invest 1997;100(12):3036–3043.
Somech R, Roifman CM: Mutation analysis should be performed to rule out gammac deficiency in children with functional severe combined immune deficiency despite apparently normal immunologic tests. J Pediatr 2005;147:555–557.
Porter BO, Scibelli P, Malek TR: Control of T cell development in vivo by subdomains within the IL-7 receptor alpha-chain cytoplasmic tail. J Immunol 2001;166:262–269.
Giliani S, Mori L, de Saint Basile G, et al: Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev 2005;203:110–126.
Puel A, Ziegler SF, Buckley RH, Leonard WJ: Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998;20(4):394–397.
Roifman CM, Zhang J, Chitayat D, Sharfe N: A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000;96:2803–2807.
Buferne M, Luton F, Letourneur F, et al: Role of CD3 delta in surface expression of the TCR/CD3 complex and in activation for killing analyzed with a CD3 delta-negative cytotoxic T lymphocyte variant. J Immunol 1992;148(3):657–664.
Haks MC, Cordaro TA, van den Brakel JH, et al: A redundant role of the CD3 gamma-immunoreceptor tyrosine-based activation motif in mature T cell function. J Immunol 2001;166:2576–2588.
Roifman CM: CD3 delta immunodeficiency. Curr Opin Allergy Clin Immunol 2004;4:479–484.
Torres PS, Alcover A, Zapata DA, et al: TCR dynamics in human mature T lymphocytes lacking CD3 gamma. J Immunol 2003;170:5947–5955.
Dadi HK, Simon AJ, Roifman CM: Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003;349:1821–1828.
Dave VP, Cao Z, Browne C, et al: CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage. EMBO J 1997;16:1360–1370.